Sept 27 (Reuters) - ZIOPHARM Oncology Inc :
* ZIOPHARM ONCOLOGY INC - APPROXIMATELY 60 POSITIONS HAVE BEEN ELIMINATED, REPRESENTING MORE THAN 50% OF ITS WORKFORCE
* ZIOPHARM ONCOLOGY INC - WILL INCUR TOTAL EXPENSES RELATING TO RESTRUCTURING OF APPROXIMATELY $3.8 MILLION FOR SEVERANCE AND TERMINATION-RELATED COSTS
* ZIOPHARM ONCOLOGY INC - EXPECTS TO RECORD RESTRUCTURING CHARGES IN Q3 OF 2021
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.